A Study To Evaluate PF-00915275 In Subjects With Type 2 Diabetes Mellitus For 4-Weeks
Status:
Terminated
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and
pharmacodynamics (PD) of PF-00915275 following administration to adult human subjects with
T2DM for 4-weeks. The primary end point is glucose lowering (24 hour mean glucose
concentration).